Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0N1WU
|
|||
| Former ID |
DAP000778
|
|||
| Drug Name |
Etodolac
|
|||
| Synonyms |
etodolac; 41340-25-4; Etodolic acid; Lodine; Ultradol; Lodine XL; Etodolacum; Etodolaco; Ramodar; AY 24236; Etodolacum [INN-Latin]; Etodolaco [INN-Spanish]; AY-24236; AY-24,236; Edolan; CCRIS 3923; 2-(1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl)acetic acid; CHEMBL622; NSC 282126; 1,3,4,9-Tetrahydro-1,8-diethylpyrano(3,4-b)indole-1-acetic acid; 1,8-Diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid; 1,8-Diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acid; Pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Pain [ICD-11: MG30-MG3Z] | Approved | [1], [2] | |
| Therapeutic Class |
Analgesics
|
|||
| Company |
Meda Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H21NO3
|
|||
| Canonical SMILES |
CCC1=C2C(=CC=C1)C3=C(N2)C(OCC3)(CC)CC(=O)O
|
|||
| InChI |
1S/C17H21NO3/c1-3-11-6-5-7-12-13-8-9-21-17(4-2,10-14(19)20)16(13)18-15(11)12/h5-7,18H,3-4,8-10H2,1-2H3,(H,19,20)
|
|||
| InChIKey |
NNYBQONXHNTVIJ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 41340-25-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9204, 143623, 224459, 855612, 5268437, 7847381, 7979205, 8149693, 8152106, 10321309, 11335322, 11360561, 11364138, 11366700, 11369262, 11372457, 11373819, 11377424, 11461533, 11466259, 11467379, 11485110, 11485958, 11489203, 11491244, 11492225, 11495058, 12012673, 14824710, 17405042, 24278407, 26612147, 26680024, 26747213, 26747214, 29222445, 46505184, 47885271, 47959585, 47959586, 48034967, 48110316, 48184861, 48259079, 48334348, 48413770, 49698757, 49857374, 50105240, 50105241
|
|||
| ChEBI ID |
CHEBI:4909
|
|||
| ADReCS Drug ID | BADD_D00850 | |||
| SuperDrug ATC ID |
M01AB08
|
|||
| SuperDrug CAS ID |
cas=041340254
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides fragilis ATCC43859
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Etodolac can be metabolized by Bacteroides fragilis ATCC43859 (log2FC = -0.814; p = 0.015). | |||
|
Studied Microbe: Bacteroides fragilis HMW 615
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Etodolac can be metabolized by Bacteroides fragilis HMW 615 (log2FC = -0.783; p = 0.042). | |||
|
Studied Microbe: Bacteroides fragilis str. 3397 T10
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Etodolac can be metabolized by Bacteroides fragilis str. 3397 T10 (log2FC = -0.374; p = 0.041). | |||
|
Studied Microbe: Bacteroides fragilis str. 3986 T(B)9
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Etodolac can be metabolized by Bacteroides fragilis str. 3986 T(B)9 (log2FC = -0.596; p = 0.016). | |||
|
Studied Microbe: Bacteroides fragilis str. DS-208
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Etodolac can be metabolized by Bacteroides fragilis str. DS-208 (log2FC = -0.614; p = 0.023). | |||
|
Studied Microbe: Bacteroides thetaiotaomicron 3731
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Etodolac can be metabolized by Bacteroides thetaiotaomicron 3731 (log2FC = -0.4; p = 0.009). | |||
|
Studied Microbe: Bacteroides thetaiotaomicron 7330
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Etodolac can be metabolized by Bacteroides thetaiotaomicron 7330 (log2FC = -0.474; p = 0.031). | |||
|
Studied Microbe: Bacteroides thetaiotaomicron VPI-5482
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Etodolac can be metabolized by Bacteroides thetaiotaomicron VPI-5482 (log2FC = -0.473; p = 0.008). | |||
|
Studied Microbe: Bacteroides uniformis ATCC 8492
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Etodolac can be metabolized by Bacteroides uniformis ATCC 8492 (log2FC = -0.791; p = 0.012). | |||
|
Studied Microbe: Bacteroides xylanisolvens DSM18836
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Etodolac can be metabolized by Bacteroides xylanisolvens DSM18836 (log2FC = -0.579; p = 0.034). | |||
|
Studied Microbe: Odoribacter splanchnicus
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Etodolac can be metabolized by Odoribacter splanchnicus (log2FC = -0.51; p = 0.007). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Blautia hansenii DSM20583
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Etodolac can be metabolized by Blautia hansenii DSM20583 (log2FC = -0.406; p = 0.044). | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7185). | |||
| REF 2 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 074819. | |||
| REF 3 | Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019 Jun;570(7762):462-467. | |||
| REF 4 | Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis. Intern Med. 2007;46(13):1055-8. | |||
| REF 5 | Induction of apoptosis by cyclooxygenase-2 inhibitors in prostate cancer cell lines. Int J Urol. 2001 Jul;8(7):S35-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.